Genotypic tumor profiling is becoming increasingly routine in the battle against cancer, and next generation sequencing (NGS) is offering a way to quickly and affordably establish baseline tumor genetics.
Platforms such as MiSeq™ and Ion Torrent™ are increasingly used to interrogate tumors using pre-defined cancer panels such as Ampliseq™ or Truseq™. The range of steps involved in a NGS workflow, combined with the sheer number of biomarkers being screened, has the potential to create unprecedented levels of variability. In order to generate results with confidence, it is therefore important to manage potential workflow variability from sample extraction and sample selection through to sequencing and variant calling.
Sources of Variability in NGS Workflows
Horizon Diagnostics has developed a Q-Seq (Quality-Sequencing) Reference Standards portfolio comprising of multiplexed DNA and FFPE samples to support the analysis and validation of NGS workflows. This allows you to:
Controlling Variability in NGS Workflows
Paragraph explaining benefits of Biocair×